262 related articles for article (PubMed ID: 18752077)
1. [Pharmacoeconomics of infection in the intensive care unit].
Grau S; Alvarez-Lerma F
Rev Esp Quimioter; 2008; 21 Spec No 1():26-34. PubMed ID: 18752077
[TBL] [Abstract][Full Text] [Related]
2. [Antibiotic pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
[TBL] [Abstract][Full Text] [Related]
3. [Can one use probabilistic protocols for antibiotic therapy in intensive care units?].
Bourdain N; Lepape A; Galzot F; Lamy B; Haessler D; Chomarat M; Grozel JM; Banssillon V
Pathol Biol (Paris); 1999 May; 47(5):584-8. PubMed ID: 10418047
[TBL] [Abstract][Full Text] [Related]
4. [The pharmacoeconomics of treatment of severe infections in intensive care].
Zambrowski JJ
Ann Fr Anesth Reanim; 2000 May; 19(5):430-5. PubMed ID: 10874445
[TBL] [Abstract][Full Text] [Related]
5. Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients.
Ancona F
Minerva Med; 2010 Oct; 101(5):319-28. PubMed ID: 21048554
[TBL] [Abstract][Full Text] [Related]
6. The pharmacoeconomics of acne treatment: where are we heading?
Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
[TBL] [Abstract][Full Text] [Related]
7. Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.
Vandijck DM; Depaemelaere M; Labeau SO; Depuydt PO; Annemans L; Buyle FM; Oeyen S; Colpaert KE; Peleman RP; Blot SI; Decruyenaere JM
Int J Antimicrob Agents; 2008 Feb; 31(2):161-5. PubMed ID: 18164599
[TBL] [Abstract][Full Text] [Related]
8. Economics of antibiotic resistance.
Sipahi OR
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
[TBL] [Abstract][Full Text] [Related]
9. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit.
Shorr AF
Crit Care Med; 2009 Apr; 37(4):1463-9. PubMed ID: 19242341
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact and relevance of antibiotic resistance.
French GL
Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
[TBL] [Abstract][Full Text] [Related]
11. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise.
Erlandsson M; Burman LG; Cars O; Gill H; Nilsson LE; Walther SM; Hanberger H;
Scand J Infect Dis; 2007; 39(1):63-9. PubMed ID: 17366015
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study.
Jang TN; Lee SH; Huang CH; Lee CL; Chen WY
J Hosp Infect; 2009 Oct; 73(2):143-50. PubMed ID: 19716203
[TBL] [Abstract][Full Text] [Related]
13. [Phamacoeconomic analysis of antibiotics use in the Clinical Center of Vojvodina].
Stefan-Mikić S; Jovanović J; Jovanović N; Aleksić-Dordević M; Cvjetković D; Krajcir I
Med Pregl; 2008; 61 Suppl 1():50-8. PubMed ID: 19248640
[TBL] [Abstract][Full Text] [Related]
14. [Reduction in cost of stay in intensive care unit with price education program of drugs].
Wang YL; Li HB; Wang XH; Xie YY
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Aug; 19(8):492-5. PubMed ID: 17708849
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomics of appropriate antimicrobial use.
Davey P
Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
[TBL] [Abstract][Full Text] [Related]
16. Possibilities for cost containment in intensive care.
Thungjaroenkul P; Kunaviktikul W
Nurs Health Sci; 2006 Dec; 8(4):237-40. PubMed ID: 17081150
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong.
Ng CK; Wu TC; Chan WM; Leung YS; Li CK; Tsang DN; Leung GM
Qual Saf Health Care; 2008 Oct; 17(5):387-92. PubMed ID: 18842981
[TBL] [Abstract][Full Text] [Related]
18. Cost savings attributable to reductions in intensive care unit length of stay for mechanically ventilated patients.
Kahn JM; Rubenfeld GD; Rohrbach J; Fuchs BD
Med Care; 2008 Dec; 46(12):1226-33. PubMed ID: 19300312
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics: disease-based management applications.
Garrelts JC
Pharm Pract Manag Q; 1996 Jul; 16(2):36-40. PubMed ID: 10161609
[TBL] [Abstract][Full Text] [Related]
20. Minimized analysis of costs applied to antimicrobial consumption in a rural area.
Sánchez CC; Nájera LH; Inchaurregui LC
Pharmacoepidemiol Drug Saf; 2001; 10(2):143-8. PubMed ID: 11499853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
